{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:16:10Z","timestamp":1760660170629,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejim.2020.06.037","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T09:48:38Z","timestamp":1593769718000},"page":"114-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Safety and efficacy of levosimendan in patients with cardiac amyloidosis"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Arzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.06.037_bib0001","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.06.037_bib0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","article-title":"Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan","volume":"159","author":"Papp","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.06.037_bib0003","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00059-018-4693-3","article-title":"Effect of levosimendan in patients with acute decompensated heart failure: a meta-analysis","volume":"44","author":"Zhou","year":"2019","journal-title":"Herz"},{"key":"10.1016\/j.ejim.2020.06.037_bib0004","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1053\/j.jvca.2015.03.023","article-title":"Levosimendan treatment for heart failure: a systematic review and meta-analysis","volume":"29","author":"Gong","year":"2015","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.ejim.2020.06.037_bib0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.acvd.2018.03.004","article-title":"Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure","volume":"111","author":"d'Humi\u00e8res","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2020.06.037_bib0006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2017.1372412","article-title":"Successful use of palliative inotrope therapy in end-stage cardiac ATTR amyloidosis","volume":"24","author":"Panhwar","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2020.06.037_bib0007","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.ejim.2020.06.037_bib0008","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ejim.2020.06.037_bib0009","first-page":"211","article-title":"Levosimendan use in several scenarios of acute heart failure","volume":"90","author":"Tavares","year":"2008","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.ejim.2020.06.037_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","author":"Aimo","year":"2020","journal-title":"Eur J Int Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520302831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520302831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:31:46Z","timestamp":1760607106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520302831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":10,"alternative-id":["S0953620520302831"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.06.037","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of levosimendan in patients with cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}